Mr. Gering is a co-founder of the Wall Street law firm of Wuersch & Gering LLP. Mr. Gering’s practice focuses on corporate, finance and securities transactions. Over the course of more than twenty-five years Mr. Gering has served as legal counsel representing clients in a broad range of corporate, regulatory and business matters pertaining to public and private companies operating in diverse industries, private equity funds, hedge funds, commodities funds, family offices, on-shore and off-shore investment companies, mutual funds, broker-dealers, financial intermediaries, banks, international stock exchanges, investment advisors, trustees and individual investors.>
Mr. Gering also has extensive experience structuring, negotiating and drafting documents relative to transactions involving mergers and acquisitions, joint ventures, strategic alliances, partnerships, licenses, distribution relationships and franchise matters. In addition, Mr. Gering advises clients on compliance with state and federal securities regulation, stock exchange listing compliance and many other legal and business matters. Mr. Gering has undertaken lead management roles on behalf of clients, including serving as Chairman of a FINRA registered broker dealer.
Mr. Gering is admitted to the bar in New York and New Jersey. He obtained his law degree from Rutgers University School of Law where he served as an Executive on the Editorial Board of Law Review. He holds the equivalent of a Master’s Degree (with Highest Honors) from an institution now affiliated with the University of Geneva, Switzerland, and he also attended the Harvard Law School post-graduate program for lawyers (Banking and Finance). Mr. Gering is fluent in English and French.
Prior to co-founding his law firm, he practiced in the corporate and securities group of the law firm of Fried, Frank, Harris, Shriver & Jacobson in New York. Mr. Gering also served as in-house counsel to a NASDAQ listed public company that was one of the first companies to obtain FDA approval to utilize artificial intelligence for medical diagnostic systems.
Mr. Gering is a member of the Business Law Section of the American Bar Association and serves as Vice President of the Banking and Finance Commission of the International Lawyers Association (Union Internationale des Avocats). Mr. Gering is a frequent lecturer and author of articles on corporate and securities matters, including writing the chapter on “Forming the Enterprise and Raising Capital” for the textbook, “Biotechnology: From Idea to Market” edited by Fred Mermelstein, PhD, Professor at Harvard Medical School, Entrepreneur in Residence at the Dana Farber Cancer Center, and Partner of Ascentia Asset Management, Richard Prince, PhD, CEO at Now Biopharma, LLC, a clinical CRO and regulatory/GxP compliance consultancy; and Carl Novina, M.D., Ph.D, Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Center; associate member of the Broad Institute of Harvard and MIT. Notably, Phillip A. Sharp, Ph.D., Nobel Laureate in Physiology/Medicine (1993), co-founder of Biogen (now Biogen Idec) and co-founder of Alnylam Pharmaceutical, has written the foreword and endorsed the book.
